

# Bronchodilator response after two methods of salbutamol nebulization in asthmatic children

Andrzej Emeryk<sup>1</sup>, Kamil Janeczek<sup>1</sup>, Ewa Markut-Miotła<sup>1</sup>, Michał Pirożyński<sup>2</sup>, Emil Florkiewicz<sup>3</sup>

<sup>1</sup>Department of Pulmonary Diseases and Children Rheumatology, Medical University of Lublin, Lublin, Poland

<sup>2</sup>Centre of Allergology, Pneumology and Emergency Medicine – Simulation Centre, Centre of Postgraduate Medical Education, Warsaw, Poland

<sup>3</sup>Non-public Medical Centre ESKULAP, Sieradz, Poland

Adv Dermatol Allergol

DOI: <https://doi.org/10.5114/ada.2022.117038>

## Abstract

**Introduction:** Salbutamol is used in bronchodilator response testing (BDRT), which is an important diagnostic tool in bronchial obstructive diseases. Most available studies compare the bronchodilator response of salbutamol administered with a pressurized metered-dose inhaler and salbutamol in a nebulization solution.

**Aim:** The spirometric evaluation of the bronchodilator response of two methods of salbutamol nebulization in asthmatic children.

**Material and methods:** A randomized, open, comparative study was conducted in which 132 children with partially controlled asthma and current bronchial obstruction determined by spirometry were enrolled. BDRT was conducted using salbutamol solution administered with either a continuous jet nebulizer (CON) or a breath-actuated jet nebulizer (BAN). The BAN group received half the dose of the drug compared to the CON group, i.e. 2.5 mg. Changes in FEV<sub>1</sub> and FEF25–75 after drug administration were calculated in relation to the baseline values.

**Results:** The change in FEV<sub>1</sub> after salbutamol administration was 16.9 ±9.7% in the BAN group and was statistically significantly higher than in the CON group (12.6 ±8.8%) ( $p = 0.026$ ). The change in FEF25–75 was 37.7 ±23.2% in the BAN group and 32.7 ±25.5% in the CON group ( $p = 0.061$ ). There were no statistically significant differences in the frequency of adverse events between the compared groups.

**Conclusions:** Salbutamol inhaled from BAN results in a better bronchodilator response than twice the nominal dose of this drug inhaled from CON, which is due to the absence of drug loss during the expiratory phase and therefore greater pulmonary deposition.

**Key words:** asthma, bronchodilator response, children, nebulization, salbutamol.

## Introduction

Short-acting  $\beta_2$ -agonists in inhalation (SABA) such as salbutamol (albuterol, levobutanolol), fenoterol and terbutaline have been standard bronchodilator drugs used as rescue medication in asthma and other chronic or acute obstructive pulmonary diseases [1–4]. SABA is also used in bronchodilator response testing (BDRT), which is an important diagnostic tool in bronchial obstructive diseases in both children and adults [1, 2, 5, 6]. Salbutamol is available in a pressurized metered-dose inhaler (pMDI), a breath-actuated metered-dose inhaler (pMDI-BA), different types of dry powder inhalers (DPIs), a metered-dose liquid inhaler (MDLI) and as a nebulization solution [7, 8]. This drug in BDRT is administered most often with

pMDI alone or via suitable valved holding chamber (VHC) or sometimes from nebulizers [5, 9–11].

The bronchodilator response (BDR) of SABA depends on many factors, including a deposited dose in the lower airways [12], polymorphism of the  $\beta_2$ -adrenergic receptors [13–15], the initial degree of obstruction of bronchi and bronchioles, and the cause and mechanism of their obturation [5]. The dose of salbutamol deposited in the tracheobronchial tree depends on the characteristics of the inhaled cloud and how the patient is breathing [16]. The characterization of the aerosol cloud of each nebulized drug is influenced by the aerosol generation method (jet/pneumatic vs. ultrasound nebulizer), in particular the characteristics of the nebulizer head, and in

---

**Address for correspondence:** Kamil Janeczek, Department of Pulmonary Diseases and Children Rheumatology, Children's University Hospital, Prof. A. Gębali 6, 20-093 Lublin, Poland, phone: +48 817185477, e-mail: [kamil.janeczek@umlub.pl](mailto:kamil.janeczek@umlub.pl)

**Received:** 30.03.2022, **accepted:** 22.04.2022.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (<http://creativecommons.org/licenses/by-nc-sa/4.0/>)

the case of jet nebulizers, also the type of compressor [8, 17]. Technical differences between nebulizers cause that the dose of medicine leaving different types of these devices may differ from each other even more than 10 times [18]. In the case of jet nebulizers, another element which can influence the clinical effectiveness of the drug is the method and technique of nebulization: continuous nebulizer vs. breath-actuated nebulizer vs. nebulizer adapting to the breathing pattern [7, 19–21].

There are relatively few studies comparing the clinical effects of the same drug inhaled from various nebulizers, especially in children [22–30]. This is due to the methodological difficulties of such studies (the technological diversity of nebulizers, calculation of drug doses) and the lack of legal regulations from the FDA or EMA that may be the basis for such comparisons [21, 31, 32].

### Aim

The main goal of the study was the spirometric evaluation of the BDR of two methods of salbutamol nebulization in asthmatic children with bronchial obstruction. The additional goal was to assess the tolerance of the inhaled drug.

### Material and methods

#### Study design

A single-site, randomized, open, comparative study was conducted in the Pulmonology Outpatient Clinic at the University Children’s Hospital (a tertiary care hospital) in Lublin (Poland) between January 2010 and May 2017. This study was approved by the Local Bioethics Committee of the Medical University of Lublin (Resolution No. KE-0254/121/2009) and performed in accordance with the Declaration of Helsinki. All participants and their parents provided written informed consent.

The primary study objective was to assess the change in forced expiratory volume in the first second (FEV<sub>1</sub>) and forced expiratory flow at 25–75% of vital capacity (FEF<sub>25–75</sub>) values 15 min after salbutamol administration using two different nebulization methods vs. baseline values in children with bronchial obstruction. The secondary ob-

jective was to assess the prevalence of typical adverse effects of SABA, such as tremors, vomiting, palpitation, increase in blood pressure and heart rate during 1 h of observation.

### Patients

Eligible participants were children aged 6 to 17 years with partially controlled asthma, recognized by the physician at least 6 months before the study and treated according to GINA recommendations [33]. The other inclusion criteria included: ability to perform correct spirometry (at least once correctly performed spirometry within 12 months before inclusion in the study), ability to perform correct nebulization with the mouthpiece (previous experience with nebulization), bronchial obstruction determined by spirometry (percent predicted FEV<sub>1</sub> (FEV<sub>1</sub>%) < 80%). Key exclusion criteria were as follows: features of respiratory tract infection in the last 4 weeks before the study, use of SABA in the last 6 h, ipratropium bromide in the last 8 h, long-acting β<sub>2</sub>-agonists (LABA) in the last day, tiotropium bromide in the last 7 days, systemic corticosteroid in the last 30 days before the study, passive and active tobacco smoking, FEV<sub>1</sub>% ≤ 50% [34].

The sample size was calculated based on a similar study in children, in which a group of 72–90 participants was sufficient [35].

### Intervention

Patients reporting to the Pulmonary Function Testing Laboratory performed spirometry, and if all inclusion criteria and none of the exclusion criteria were met, they were randomly assigned to one of two therapeutic groups. Children in the first group received a standard salbutamol dose of 5 mg in 2.5 ml of nebulization solution (Steri-Neb Salamol, salbutamol sulphate solution, 5 mg/2.5 ml, IVAX Pharmaceuticals, UK) inhaled by continuous jet nebulizer (CON). In this group (CON group), the Porta-Neb compressor (MEDIC-AID, UK) with a PARI LC PLUS nebulizer head (PARI Medical Ltd, UK) was used (a typical device used for nebulization in our hospital) (Table 1) [36–38]. The residual volume (i.e. the volume of drug remaining in the nebulization chamber at the end of nebulization) of this nebulizer is 1 ml,

**Table 1.** Characteristics of the devices used for salbutamol nebulization [8, 36–38]

Parameter	Porta-Neb compressor + PARI LC PLUS nebulizer head (CON)	MARIN MP3 compressor + RF6 PLUS nebulizer head (BAN)
Flow rate [l/min]	6.0	15.5
Aerosol output rate [ml/min]	0.3	0.8
Residual volume of nebulization chamber [ml]	1.0	0.9
MMAD [μm]	3.8	2.8
FPF (%)	60.0	76.0

MMAD – mass median aerodynamic diameter, FPF – fine particle fraction.

therefore the total dose of salbutamol used per patient in this group was 7 mg (3.5 ml). Children in the second group received salbutamol from the breath-actuated jet nebulizer (BAN). In this group (BAN group), the MARIN MP3 compressor (Medbryt, Poland) with a RF6 PLUS nebulizer head (FLAEM NUOVA S.p.A., Italy) was used (Table 1). The salbutamol dose was halved in this group vs. the recommended dose for CON, i.e. to 2.5 mg (1.25 ml of drug solution). This was due to mathematical calculations (explanation in the discussion) and previous studies with BAN [39]. Also, the dose was increased in this group by the volume necessary to fill the residual volume of the nebulization chamber (0.9 ml). Therefore, a total of 4.3 mg of the drug was added into the nebulization chamber (2.15 ml of salbutamol solution). In both groups the drug was used without additional dilution. All subjects were previously instructed to maintain their natural breathing pattern until the medication was completely nebulized. Inhalation was performed using a mouthpiece. 15 min after the administration of salbutamol, the pulmonary function test was repeated.

Children were observed for 1 hour from the beginning of salbutamol nebulization. Their heart rate and blood pressure was assessed every 15 min. Elevated blood pressure was recognized based on percentile grid for the Polish population of school children and adolescents [40], and tachycardia based on available standards in children [41, 42]. In addition, symptoms reported by patients were recorded.

### Spirometry

As mentioned above, a flow-volume loop was recorded before and 15 min after salbutamol nebulization using a KoKo PFT spirometer (nSpire Health, Inc., USA). Children performed spirometry three times and the curve with the best FEV<sub>1</sub> and FVC values was selected for further statistical analysis. Changes in FEV<sub>1</sub> and FEF25–75

after drug administration were calculated in relation to the baseline values in percentage ( $\Delta$ FEV<sub>1</sub>,  $\Delta$ FEF25–75) according to the formulas [43]:

- $\Delta$ FEV<sub>1</sub> = (FEV<sub>1</sub> after salbutamol – FEV<sub>1</sub> baseline)/(FEV<sub>1</sub> baseline) × 100%,
- $\Delta$ FEF25–75 = (FEF25–75 after salbutamol – FEF25–75 baseline)/(FEF25–75 baseline) × 100%.

### Randomization

The randomization list was generated using Random Allocation Software. Participants drew a card with a unique number that assigned them to the appropriate group (CON or BAN).


### Statistical analysis

The collected data were analysed using IBM SPSS Statistics 25. Outcomes of the two nebulization methods were compared using the Mann-Whitney *U* test. The  $\chi^2$  test was used to check whether there is a significant relationship between the nominal variables. *P*-value of less than 0.05 was considered statistically significant.

### Results

Participants were selected from among 248 children with bronchial obstruction admitted to the Pulmonology Outpatient Clinic at the University Children's Hospital in Lublin. A total of 132 BDRTs were performed (Figure 1). The characteristics of the studied groups are summarized in Table 2.

The mean baseline FEV<sub>1</sub>% was 70.5 ± 8.9% in the CON group and 67.4 ± 11.6% in the BAN group (*p* = 0.216). There was also no statistically significant difference between the compared groups in terms of baseline FEF25–75% (*p* = 0.067) (Table 3).



CON – continuous jet nebulizer, BAN – breath-actuated jet nebulizer.

Figure 1. Participant flow diagram

**Table 2.** Demographic and clinical characteristics of the studied groups

Parameter	CON group (n = 66)	BAN group (n = 66)	P-value
Age, mean ± SD [years]	11.2 ±3.1	11.9 ±3.4	> 0.05
Sex, n, male/female	44/22	46/20	> 0.05
IgE-dependent asthma, n (%)	60 (90.9)	63 (95.5)	> 0.05
Baseline heart rate, mean ± SD [beats per minute]	82.6 ±8.4	81.4 ±7.8	> 0.05
Baseline value of blood pressure [mm Hg]	106/62	109/65	> 0.05
Baseline elevated blood pressure*, n (%)	3 (4.6)	2 (3.0)	> 0.05
Asthma control medications, n (%):			
Low dose ICS	41 (62.1)	39 (59.1)	> 0.05
Medium dose ICS	3 (4.6)	2 (3.0)	> 0.05
ICS + LABA	22 (33.3)	25 (37.9)	> 0.05

\* ≥ 95<sup>th</sup> percentile, ICS – inhaled corticosteroid, LABA – long-acting β2-agonists.

**Table 3.** Bronchodilator response to salbutamol in the CON and BAN groups

Parameter	CON group (n = 66)	BAN group (n = 66)	P-value
Baseline FEV <sub>1</sub> %:			0.216
Mean ± SD (%)	70.5 ±8.9	67.4 ±11.6	
Min.–max. (%)	51.0–79.0	52.0–79.0	
Baseline FEF25–75%:			0.067
Mean ± SD (%)	55.4 ±11.8	51.5 ±13.7	
Min.–max. (%)	28.0–79.0	16.0–87.0	
ΔFEV <sub>1</sub> :			0.026
Mean ± SD (%)	12.6 ±8.8	16.9 ±9.7	
Min.–max. (%)	1.0–47.0	1.0–49.0	
ΔFEF25–75:			0.061
Mean ± SD (%)	32.7 ±25.5	37.7 ±23.2	
Min.–max. (%)	2.0–116.0	10.0–125.0	

FEV<sub>1</sub> % – forced expiratory volume in the first second as a percentage of the predicted value, FEF25–75% – forced expiratory flow at 25–75% of vital capacity as a percentage of the predicted value; ΔFEV<sub>1</sub> or ΔFEF25–75 – changes in FEV<sub>1</sub> or FEF25–75 after SABA administration in relation to the baseline values in percentage

The ΔFEV<sub>1</sub> was 16.9 ±9.7% in the BAN group and was statistically significantly higher than in the CON group (12.6 ±8.8%) (p = 0.026). The ΔFEF25–75 was 37.7 ±23.2% in the BAN group and 32.7 ±25.5% in the CON group (p = 0.061) (Table 3).

Adverse events were observed during the first hour after the beginning of nebulization in 9 patients (5 from the BAN group and 4 from the CON group). A total of 15 adverse events were recorded in the BAN group and 14 in the CON group. There were no statistically significant differences in the frequency of these symptoms between the compared groups of children (p = 0.68) (Table 4).

**Table 4.** Adverse effects observed during bronchodilator response tests with salbutamol in CON and BAN groups

Symptoms	CON group (n = 66)	BAN group (n = 66)
Muscle tremors	2	3
Headache	0	1
Tachycardia	2	3
Elevated blood pressure	4	5
Decrease in diastolic blood pressure	1	0
Irritation of the oral mucosa and throat	2	0
Muscle spasms	1	2
Nausea	2	1

## Discussion

As mentioned earlier, jet nebulizers come in several varieties: conventional or continuous (CON), breath-assisted, breath-enhanced, breath-actuated (BAN) and breath-adapted [7, 17, 19, 44, 45]. Each group of jet nebulizers used with the same drug and at the same dose can produce significantly different pulmonary deposition and possibly a different clinical effect [18, 46, 47]. This was confirmed by Finlay et al., who showed that the lung deposition of salbutamol inhaled from 19 different nebulizers ranged from 3.1% to 23.4% (p < 0.01) of the nominal dose placed in the nebulizer [23]. In another study, Walz-Jung et al. showed significant differences between 9 different jet nebulizers during the nebulization of salbutamol. The drug delivery rate varied from 67 μg/min to 196 μg/min [48]. These differences result from significantly different technical parameters of individual components of nebulization devices, such as compressor, nebulizer head, and residual volume of the

nebulization chamber. This, in turn, translates into the emitted dose and the characteristics of the aerosol cloud (mass median aerodynamic diameter – MMAD, fine particle fraction – FPF, geometric standard deviation – GSD) [49–51]. However, the final clinical effect of a nebulized drug also depends on the patient's breathing pattern (tidal volume, respiratory rate, inspiration to expiration ratio) and the functional state of the patient's airways [52, 53].

The relationship between MMAD and the bronchodilatory effect of salbutamol was demonstrated by Usmani *et al.* [16]. The researchers showed a greater bronchodilatory effect of this drug assessed by measuring FEV<sub>1</sub> and FEF<sub>25–75</sub> in adults with asthma during the inhalation of monodisperse aerosol with a MMAD 3.0 and 6.0 µm than that with a MMAD 1.5 µm. In our study, the MMAD of both aerosol clouds were slightly different (3.8 µm for CON, 2.8 µm for BAN). However, these values were similar to those which were effective according to the data from the study by Usmani *et al.* [16].

There are relatively few studies comparing the spirometric and clinical effects of salbutamol nebulization from various nebulizers in children with asthma [27, 29, 54, 55]. Much more reports concern the comparison of the efficacy of salbutamol nebulization with salbutamol administered via pMDI [56, 57]. This is due to the still low availability of BANs, the rapid development of this group of nebulizers only in the last 20 years, their large diversity, as well as the difficulty in assessing the actual lung deposition of inhaled drugs by *in vivo* studies in children.

BANs are usually characterized by greater lung deposition and a better clinical effect versus CONs. Nikander *et al.* in a series of their studies showed that in 5–15-year-old asthmatic children, the average mass of budesonide inhaled from the BAN ranged from 17.1% to 21.6% of the nominal dose [58–60]. In the case of nebulization of the same drug but from a CON, this value was two times lower (8.9% to 12.2%). Another study conducted by researchers from Taiwan provides similar observations [55]. They showed that the nebulization of the same dose of terbutaline using BAN is better than using CON in improving spirometric parameters in asthmatic children, which may be related to higher lung deposition of the drug in the first group. Wilkinson *et al.* recorded shorter lengths of stay in emergency departments in children with moderate to severe asthma exacerbation treated with BAN compared to CON (118 vs. 163 min,  $p = 0.0002$ ), without differences with respect to admission rates, changes in asthma scores, albuterol side effects, or readmission rates [27]. On the other hand, the study by Parone *et al.* demonstrated no clinical difference between the bronchodilator nebulization from BAN and CON in adult patients with dyspnoea and wheezing [26]. In another study, albuterol delivered via CON resulted in a significantly greater improvement in FEV<sub>1</sub> than albuterol delivered by a breath-enhanced nebulizer [29]. As shown

above, the results obtained by the researchers are inconsistent.

The analysis of the nebulization process from the RF6 PLUS with MARIN MP3 device (BAN group) indicates that about 1.25 ml of the solution, i.e. about 2.5 mg of salbutamol (emitted dose) left the nebulization chamber. Bearing in mind that nebulization occurred only during the inspiratory phase, it should be assumed that about 2.5 mg of salbutamol reaches the patient's respiratory tract (deposited dose) [36]. In the case of inhalation from the PARI LC PLUS with Porta-Neb device (CON group), the emitted dose was 2.5 ml of the solution, i.e. 5.0 mg of salbutamol. This inhaler provides continuous aerosol during inhalation, exhalation, and breath-holding, causing the release of aerosol to ambient air during exhalation (which is prolonged in a child with bronchial obstruction – up to 80% of the respiratory cycle) and anytime when the patient is not breathing. Due to the large loss of the drug caused by the characteristics of this inhaler, a maximum of 20% of the dose, i.e. about 1.0 mg of salbutamol (deposited dose) reached the respiratory tract [19, 58]. This may explain the weaker bronchodilatory effect in the CON vs. BAN group.

Our results are in line with those presented by Sabato *et al.*, in which the dose of 2.5 mg of salbutamol from BAN was more clinically effective than 10 mg of this drug from CON, which was associated with greater deposition of the drug in the bronchi in the former group [54]. The evidence for the above is also provided by Nikander *et al.* [58]. Thus, in our study, the dose of salbutamol in the BAN vs. CON group was reduced twice. We showed a better bronchodilatory effect of salbutamol assessed by FEV<sub>1</sub> in the group inhaling from BAN. The values of mid-expiratory flows assessed by FEF<sub>25–75</sub> improved by over 30% in relation to the baseline values in both groups, more clearly in the BAN group, but these differences did not reach statistical significance. This can be explained by the characteristics of the aerosol clouds produced by both inhalers (Table 1), which indicate the possibility of a greater deposition of the drug in the larger bronchi [59, 60].

Various side effects associated with the use of nebulization forms of salbutamol have been reported in children with asthma, including hypokalaemia and lactic acidosis [61–63]. They were reported more often in children treated with SABA using the CON, than pMDI with VHC, and the main symptom was tachycardia [64, 65]. Our study showed similar rates of side effects in both groups despite the fact that twice the nominal salbutamol dose was used in the CON group than in the BAN group. Similar observations are provided by Sabato *et al.* and Wilkinson *et al.* [27, 54]. In turn, Lin *et al.* showed that administration of the same dose of terbutaline from two different types of jet nebulizers resulted in a higher heart rate in the BAN group vs. CON group, which the authors explain with greater lung deposition of the drug in the first group [55].

The work has some limitations. Firstly, in the CON group, the Porta-Neb compressor was used in combination with the PARI LC PLUS nebulizer head instead of the recommended Medic-Aid Sidestream (for rhDNase nebulization) or Medic-Aid Ventstream or Turret (for ICS nebulization) [37]. This was due to the technical and financial limitations of our hospital. However, it should be noted that the above recommendations regarding the combination of the Porta-Neb compressor with the appropriate nebulizer heads apply to the inhalation of rhDNase and ICS, while there are no such recommendations for SABA. Secondly, the dose of salbutamol for the BAN group was determined based on theoretical assumptions, because there were no literature data (algorithms) on how to convert SABA doses administered from CON to clinically equivalent doses administered from BAN. Thirdly, due to the different appearance and characteristics of the work of both nebulizers, it was impossible to blind the researcher and patients.

## Conclusions

Salbutamol inhaled from BAN by children with bronchial obstruction results in a better bronchodilator response than twice the nominal dose of this drug inhaled from CON, which is due to the absence of drug loss during the expiratory phase and therefore greater pulmonary deposition.

## Conflict of interest

The authors declare no conflict of interest.

## References

- Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA), Update 2021. Available on the website: <https://ginasthma.org/gina-reports/>
- Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2021 report. Available on the website: <https://goldcopd.org/2021-gold-reports/>
- Kose M, Ozturk MA, Poyrazoğlu H, et al. The efficacy of nebulized salbutamol, magnesium sulfate, and salbutamol/magnesium sulfate combination in moderate bronchiolitis. *Eur J Pediatr* 2014; 173: 1157-60.
- Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. *Cochrane Database Syst Rev* 2005; 4: CD003428.
- Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. *Eur Respir J* 2005; 26: 948-68.
- Ducharme FM, Dell SD, Radhakrishnan D, et al. Diagnosis and management of asthma in preschoolers: a Canadian Thoracic Society and Canadian Paediatric Society position paper. *Can Respir J* 2015; 22: 135-43.
- Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. *Lancet* 2011; 377: 1032-45.
- Laube BL, Janssens HM, de Jongh FHC, et al. What the pulmonary specialist should know about the new inhalation therapies. *Eur Respir J* 2011; 37: 1308-31.
- Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1986; 133: 814-9.
- Eiser NM, Phillips C, Wooler PA. Does the mode of inhalation affect the bronchodilator response in patients with severe COPD? *Respir Med* 2001; 95: 476-83.
- Li J, Zhao M, Hadeer M, et al. Dose response to transnasal pulmonary administration of bronchodilator aerosols via nasal high-flow therapy in adults with stable chronic obstructive pulmonary disease and asthma. *Respiration* 2019; 98: 401-9.
- Visser R, Kelderman S, de Jongh FHC, et al. Reversibility of pulmonary function after inhaling salbutamol in different doses and body postures in asthmatic children. *Respir Med* 2015; 109: 1274-9.
- Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the b2-adrenoceptor and response to albuterol in children with and without a history of wheezing. *J Clin Invest* 1997; 100: 3184-8.
- Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial. *Lancet* 2004; 364: 1505-12.
- Brehm JM, Man Tse S, Croteau-Chonka DC, et al. A genome-wide association study of post-bronchodilator lung function in children with asthma. *Am J Respir Crit Care Med* 2015; 192: 634-7.
- Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta-2-agonist particle size. *Am J Respir Care Med* 2005; 172: 1497-504.
- Martin AR, Finlay WH. Nebulizers for drug delivery to the lungs. *Exp Opin Drug Deliv* 2015; 12: 889-900.
- Boe J, Dennis JH, O'Driscoll BR, et al. European Respiratory Society Guidelines on the use of nebulisers. *Eur Respir J* 2001; 18: 228-42.
- Rau JL, Ari A, Restrepo RD. Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric. *Respir Care* 2004; 49: 174-9.
- Arunthari V, Bruinsma RS, Lee AS, Johnson MM. A prospective, comparative trial of standard and breath-actuated nebulizer: efficacy, safety and satisfaction. *Respir Care* 2012; 57: 1242-7.
- Hatley RH, Byrne SM. Variability in delivered dose and respirable delivered dose from nebulizers: are current regulatory testing guidelines sufficient to produce meaningful information? *Med Devices* 2017; 10: 17-28.
- Nakanishi AK, Lamb BM, Foster C, Rubin BK. Ultrasonic nebulization of albuterol is no more effective than jet nebulization for the treatment of acute asthma in children. *Chest* 1997; 111: 1505-8.
- Finlay WH, Stapleton KW, Zuberbuhler P. Variations in predicted regional lung deposition of salbutamol sulphate between 19 nebulizer types. *J Aerosol Med* 1998; 11: 65-80.
- Ram FS. Clinical efficacy of inhaler devices containing beta(2)-agonist bronchodilators in the treatment of asthma: cochrane systematic review and meta-analysis of more than 100 randomized, controlled trials. *Am J Respir Med* 2003; 2: 349-65.
- Govoni M, Poli G, Acerbi D, et al. Pharmacokinetic and tolerability profiles of tobramycin nebulizer solution 300 mg/

- 4 ml administered by PARI eFlow<sup>®</sup> rapid and PARI LC Plus<sup>®</sup> nebulisers in cystic fibrosis patients. *Pulm Pharmacol Ther* 2013; 26: 249-55.
26. Parone D, Stauss M, Reed CR, et al. A comparative study of two nebulizers in the emergency department: breath-actuated nebulizer and handheld nebulizer. *J Emerg Nurs* 2014; 40: 131-7.
27. Wilkinson M, King B, Iyer S, et al. Comparison of a rapid albuterol pathway with a standard pathway for the treatment of children with a moderate to severe asthma exacerbation in the emergency department. *J Asthma* 2018; 55: 244-51.
28. Murayama N, Murayama K. Comparison of the clinical efficacy of salbutamol with jet and mesh nebulizers in asthmatic children. *Pulm Med* 2018; 2018: 1648652.
29. Gardiner MA, Wilkinson MH. Randomized clinical trial comparing breath-enhanced to conventional nebulizers in the treatment of children with acute asthma. *J Pediatr* 2019; 204: 245-9.
30. Soyer Ö, Kahveci M, Büyüktiryaki B, et al. Mesh nebulizer is as effective as jet nebulizer in clinical practice of acute asthma in children. *Turk J Med Sci* 2019; 49: 1008-13.
31. Fuglsang A. The US and EU regulatory landscapes for locally acting generic/hybrid inhalation products intended for treatment of asthma and COPD. *J Aerosol Med Pulm Drug Deliv* 2012; 25: 243-7.
32. Evans C, Cipolla D, Chesworth T, et al. Equivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop report. *J Aerosol Med Pulm Drug Deliv* 2012; 25: 117-39.
33. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA), Update 2010. Available on the website: <https://ginasthma.org/archived-reports/>
34. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J* 2005; 26: 319-38.
35. Bussamra MH, Stelmach R, Rodrigues JC, Cukier A. A randomized, comparative study of formoterol and terbutaline dry powder inhalers in the treatment of mild to moderate asthma exacerbations in the pediatric acute care setting. *Ann Allergy Asthma Immunol* 2009; 103: 248-53.
36. Kendrick AH, Smith EC, Wilson RSE. Selecting and using nebulizer equipment. *Thorax* 1997; 52: 92-101.
37. Instructions for using the PARI LC PLUS. Available on the website: [https://www.pari.com/fileadmin/user\\_upload/PARI.com-INT/Documents/IFU/022D2004-Instructions-for-use-PARI-LC-PLUS.pdf](https://www.pari.com/fileadmin/user_upload/PARI.com-INT/Documents/IFU/022D2004-Instructions-for-use-PARI-LC-PLUS.pdf)
38. Instructions for using the RF6 PLUS. Available on the website: <https://www.manualslib.com/manual/2144716/Flaem-Rf6-Plus.html#manual>
39. Lipworth BJ, Sims EJ, Taylor K, et al. Dose-response to salbutamol via a novel palm sized nebuliser (Aerodose Inhaler), conventional nebulizer (Pari LC Plus) and metered dose inhaler (Ventolin Evohaler) in moderate to severe asthmatics. *Br J Clin Pharmacol* 2005; 59: 5-13.
40. Litwin M, Niemirska A, Obrycki Ł, et al. Guidelines of the Pediatric Section of the Polish Society of Hypertension on diagnosis and treatment of arterial hypertension in children and adolescents. *Arterial Hypertension* 2018; 22: 45-73.
41. Fleming S, Thompson M, Stevens R, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years: a systematic review of observational studies. *Lancet* 2011; 377: 1011-8.
42. de Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation* 2015; 132: 526-42.
43. Boros P, Franczuk M, Wesotowski S. Zasady interpretacji wyników badania spirometrycznego. Zalecenia Polskiego Towarzystwa Chorób Płuc (dawniej Polskie Towarzystwo Ftyzjopneumonologiczne) dotyczące wykonywania badań spirometrycznych. *Pneum Alergol Pol* 2006; 74: 1-23.
44. Rubin BK, Williams RW. Emerging aerosol drug delivery strategies: from bench to clinic. *Adv Drug Deliv Rev* 2014; 75: 141-8.
45. Ari A. Jet, ultrasonic, and mesh nebulizers: an evaluation of nebulizers for better clinical outcomes. *Eurasian J Pulmonol* 2014; 16: 1-7.
46. Daniels T, Mills N, Whitaker P. Nebuliser systems for drug delivery in cystic fibrosis. *Cochrane Database of Syst Rev* 2013; 30: CD007639.
47. Scherer T, Geller DE, Owyang L, et al. A technical feasibility study of dornase alfa delivery with eFlow<sup>®</sup> vibrating membrane nebulizers: aerosol characteristics and physicochemical stability. *J Pharm Sci* 2011; 100: 98-109.
48. Walz-Jung H, Krämer I, Kamin W. Drug output and aerosol characteristics of different Jet nebulisers for adults while simulating the nebulisation of salbutamol. *Pneumologie* 2018; 72: 820-31.
49. Sidler-Moix AL, Di Paolo ER, Dolci U, et al. Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model. *Respir Care* 2015; 60: 38-46.
50. Galindo-Filho VC, Ramos ME, Rattes CSF, et al. Radioaerosol pulmonary deposition using mesh and Jet nebulizers during noninvasive ventilation in healthy subjects. *Respir Care* 2015; 60: 1238-46.
51. Pitance L, Vecellio L, Leal T, et al. Delivery efficacy of a vibrating mesh nebulizer and a jet nebulizer under different configurations. *J Aerosol Med Pulm Drug Deliv* 2010; 23: 389-96.
52. Berlinski A, Willis JR. Effect of tidal volume and nebulizer type and position on albuterol delivery in a pediatric model of mechanical ventilation. *Respir Care* 2015; 60: 1424-30.
53. Ari A, Atalay OT, Harwood R, et al. Influence of nebulizer type, position, and bias flow on aerosol delivery in simulated pediatric and adult lung models during mechanical ventilation. *Respir Care* 2010; 55: 845-51.
54. Sabato K, Ward P, Hawk W, et al. Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department. *Respir Care* 2011; 56: 761-70.
55. Lin YZ, Huang FY. Comparison of breath-actuated and conventional constant-flow jet nebulizers in treating acute asthmatic children. *Acta Paediatr Taiwan* 2004; 45: 73-6.
56. Staggs L, Peek M, Southard G, et al. Evaluating the length of stay and value of time in a pediatric emergency department with two models by comparing two different albuterol delivery systems. *J Med Econ* 2012; 15: 704-11.
57. Benito-Fernandez J, Gonzalez-Balenciaga M, Capape-Zache S, et al. Salbutamol via metered-dose inhaler with spacer versus nebulization for acute treatment of pediatric asthma in the emergency department. *Pediatr Emerg Care* 2004; 20: 656-9.
58. Nikander K, Bisgaard H. Impact of constant and breath-synchronized nebulization on inhaled mass of nebulized budesonide in infants and children. *Pediatr Pulmonol* 1999; 28: 187-93.
59. Nikander K, Turpeinen M, Wollmer P. Evaluation of pulsed and breath-synchronized nebulization of budesonide as

- a means of reducing nebulizer wastage of drug. *Pediatr Pulmonol* 2000; 29: 120-6.
60. Nikander K, Agertoft L, Pedersen S. Breath-synchronized nebulization diminishes the impact of patient-device interfaces (face mask or mouthpiece) on the inhaled mass of nebulized budesonide. *J Asthma* 2000; 37: 451-9.
  61. Kemp J, Turck CJ, York JM. Evaluation of albuterol 1.25 mg and 0.62 mg for nebulization in 6- to 12-year-old children with moderately severe asthma. *Adv Ther* 2007; 24: 463-77.
  62. Lauritsen L, Sahl C, Thorsen S. Nebulized salbutamol as a possible cause of lactate acidosis in a patient with acute asthma. *Ugeskr Laeger* 2013; 175: 111-2.
  63. Hartman S, Merkus P, Maseland M, et al. Hypokalaemia in children with asthma treated with nebulised salbutamol. *Arch Dis Child* 2015; 100: 970-2.
  64. Castro-Rodriguez JA, Rodrigo GJ, E Rodríguez-Martínez CE. Principal findings of systematic reviews of acute asthma treatment in childhood. *J Asthma* 2015; 52: 1038-45.
  65. Pollock M, Sinha IP, Hartling L, et al. Inhaled short-acting bronchodilators for managing emergency childhood asthma: an overview of reviews. *Allergy* 2017; 72: 183-200.